What does cannabis research say about multiple sclerosis? We've analyzed 8 peer-reviewed studies to give you an honest, evidence-based overview.
Multiple high-quality studies support cannabis for this condition.
Study found evidence of effectiveness
* Outcomes are based on our curated selection of research reviews. Individual study quality varies.
About This Research Summary: The information below aggregates findings from multiple peer-reviewed studies on cannabis and multiple sclerosis. This is for educational purposes only.
Research summaries are our interpretations of published studies. Individual responses to cannabis vary significantly. These findings do not guarantee similar results for any individual.
Study data sourced from PubMed®. Not evaluated by the FDA. See our Research Content Policy.
Multiple Sclerosis (MS) is a chronic autoimmune disease affecting approximately 1 million Americans. The immune system attacks the protective myelin sheath around nerve fibers, disrupting communication between the brain and body. This causes a wide range of symptoms that vary dramatically between individuals. Common MS symptoms include muscle spasticity (stiffness and spasms), pain (both neuropathic and musculoskeletal), fatigue, bladder dysfunction, and mobility problems. Many patients also experience "invisible" symptoms like cognitive fog and depression. The disease typically follows a relapsing-remitting pattern, though progressive forms also exist. Standard MS treatments include disease-modifying therapies to slow progression and symptomatic treatments for specific issues. However, spasticity and pain remain challenging to manage, leading many MS patients to explore cannabis—which has some of the strongest evidence in neurology.
Cannabis interacts with the endocannabinoid system to modulate muscle tone and reduce spasticity. THC acts on CB1 receptors in motor areas of the brain and spinal cord, helping to relax tense muscles and reduce involuntary spasms. This is why Sativex (nabiximols), a THC:CBD spray, is approved in many countries specifically for MS spasticity. For MS pain, cannabinoids work through both central and peripheral mechanisms. Neuropathic pain—caused by nerve damage from MS—may be particularly responsive because cannabinoids modulate pain signaling at multiple levels of the nervous system. Beyond spasticity and pain, some MS patients report improvements in bladder function, sleep, and overall quality of life with cannabis. The anti-inflammatory properties of cannabinoids are also theoretically relevant to MS, though evidence for disease modification is limited.
Note: This information summarizes research findings and is not medical advice. Consult a healthcare provider before using cannabis for any medical condition.
Based on our analysis of peer-reviewed studies on cannabis and multiple sclerosis:
Based on research, these cannabinoids show the most promise for multiple sclerosis:
The THC:CBD combination (as in Sativex) has the strongest evidence for MS spasticity. The 1:1 ratio provides muscle-relaxing effects while CBD may moderate side effects. This is the evidence-based first choice.
THC alone can effectively reduce spasticity and pain. May be preferred if CBD is cost-prohibitive or THC:CBD products aren't providing adequate relief. Watch for side effects.
CBD alone has less evidence for spasticity than THC. May help with inflammation and as an add-on but is generally not sufficient as sole treatment for significant MS symptoms.
Individual responses vary. Work with a healthcare provider to determine the best approach for your situation.
MS spasticity often requires higher doses than other conditions. Sativex trials used up to 12 sprays daily (32mg THC + 30mg CBD), titrated slowly over weeks. Start much lower and increase gradually. For non-pharmaceutical cannabis, begin with 2.5-5mg THC and increase every few days until spasticity improves or side effects limit further increases. Most patients need 15-30mg THC daily for meaningful spasticity relief. Timing can be strategic—some patients use cannabis specifically before stretching or physical therapy to reduce spasticity and improve range of motion. Others use it at night when spasms often worsen. Work with a neurologist familiar with cannabinoid medicine. MS medications can interact with cannabis, and dosing needs may change with disease activity.
Dosing information is based on clinical research and is for educational purposes only. Optimal dosing varies by individual, product formulation, and administration method. Always start with the lowest effective dose and titrate slowly under medical supervision.
When considering cannabis for multiple sclerosis, be aware of these potential concerns:
Discuss these considerations with your healthcare provider before starting cannabis therapy.
Sativex (THC:CBD spray) is approved in 30+ countries for MS spasticity based on clinical trials. A controlled trial found 30% or greater spasticity improvement, and a 2019 study found cannabis helped even when first-line treatments failed.
Source: Novotna et al., European Journal of Neurology, 2011 (PMID: 20718792)
MS has some of the strongest evidence for medical cannabis in neurology. Multiple controlled trials support THC:CBD for spasticity, leading to Sativex approval in 30+ countries. Evidence also supports pain relief in MS patients.
Source: Multiple clinical trials, Sativex approval data
There is no evidence that cannabis slows MS disease progression or repairs nerve damage. Cannabis is for symptom management (spasticity, pain) only. Continue prescribed disease-modifying therapies for MS.
Source: No disease-modification evidence in clinical trials
THC:CBD combinations have the strongest evidence for MS spasticity. Sativex uses a 1:1 THC:CBD ratio. THC is the primary muscle-relaxing component, while CBD may reduce side effects and add anti-inflammatory benefits.
Source: Sativex clinical trial data
Common questions about cannabis for multiple sclerosis:
These 2024 clinical practice guidelines, based on 70 studies, conclude that cannabis-based medicines show "moderate benefit" for chronic pain and also help related conditions like sleep problems and anxiety. The guidelines provide practical dosing and titration recommendations for clinicians.
This comprehensive umbrella review of 101 meta-analyses found high-certainty evidence that CBD effectively reduces seizures in epilepsy, and cannabis-based medicines help chronic pain (30% pain reduction), MS spasticity, and IBD—but also identified clear risks during pregnancy, for mental health, and while driving.
This scoping review found cannabis has been shown useful for both acute and chronic pain, with the strongest evidence for MS-related pain and as an adjunct in cancer pain. However, evidence is weak for neuropathic pain, rheumatic conditions, and headache, and there is no strong evidence for using cannabis to reduce opioid use.
This Cochrane review found that cannabis-based medicines may reduce spasticity and chronic pain in multiple sclerosis, but evidence quality is limited. Nabiximols (Sativex) shows the most evidence for MS spasticity, though side effects are common.
This rigorous meta-analysis of 104 studies found cannabis provides modest pain relief—about 1 in 24 patients benefit—but with a high side effect burden: 1 in 6 experience harm. The authors concluded it "seems unlikely that cannabinoids are highly effective medicines" for chronic pain.
This comprehensive review of 79 trials found moderate-quality evidence that cannabinoids are effective for chronic pain and spasticity, with most studies showing improvement in symptoms.
Smoked cannabis was superior to placebo in symptom and pain reduction in participants with treatment-resistant spasticity. Future studies should examine whether different doses can result in similar beneficial effects with less cognitive impact.
Patients with MS who responded to initial cannabis spray treatment achieved twice the spasticity relief compared to placebo in this large Phase III trial.
Our reviews are just a starting point. Browse thousands more studies on PubMed for multiple sclerosis.
Multiple sclerosis is a qualifying condition in virtually all states with medical marijuana programs. It was among the first conditions listed in many states due to the strength of evidence for spasticity.
Research Summary Disclaimer
This content represents our interpretation of published scientific research for educational purposes. It should not be used to make treatment decisions without consulting a qualified healthcare provider. Individual results may vary from study findings.
FDA Notice
These statements have not been evaluated by the FDA. Cannabis is not intended to diagnose, treat, cure, or prevent any disease. The FDA has not approved cannabis for any medical condition except specific prescription medications.
Copyright & Fair Use
Research summaries are provided under fair use (17 U.S.C. § 107) for educational purposes. We provide brief summaries with attribution, not full reproductions. All studies remain the intellectual property of their respective authors and publishers.
For complete information, see our Terms of Use and Research Content Policy.
